Arena Pharmaceuticals, Inc. (ARNA)
(Delayed Data from NSDQ)
$47.60 USD
+1.62 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.68 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.60 USD
+1.62 (3.52%)
Updated May 3, 2019 04:00 PM ET
After-Market: $47.68 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?
by Zacks Equity Research
On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).
Is Vertex Pharma (VRTX) Poised for a Turnaround in 2017?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) main therapeutic area of focus is cystic fibrosis (CF). Presently, the company markets two medicines for the disease, Kalydeco and Orkambi.